1 - 25 of 27 results for author:"King C.R." in Literature citations
Results Customize
› Repeat search in UniProtKB (71)
| Gamma-glutamyl carboxylase and its influence on warfarin dose. King C.R., Deych E., Milligan P., Eby C., Lenzini P., Grice G., Porche-Sorbet R.M., Ridker P.M., Gage B.F. Thromb. Haemost. 104:750-754(2010) · Mapped (5) |
| Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Kahl C.A., Bonnell J., Hiriyanna S., Fultz M., Nyberg-Hoffman C., Chen P., King C.R., Gall J.G. Vaccine 28:5691-5702(2010) · UniProtKB (30) |
| Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. McLeod H.L., Sargent D.J., Marsh S., Green E.M., King C.R., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Thibodeau S.N. et al. J. Clin. Oncol. 28:3227-3233(2010) · Mapped (61) |
| Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Ferder N.S., Eby C.S., Deych E., Harris J.K., Ridker P.M., Milligan P.E., Goldhaber S.Z., King C.R., Giri T., McLeod H.L. et al. J. Thromb. Haemost. 8:95-100(2010) · Mapped (9) |
| Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. Lenzini P.A., Grice G.R., Milligan P.E., Dowd M.B., Subherwal S., Deych E., Eby C.S., King C.R., Porche-Sorbet R.M., Murphy C.V. et al. J. Thromb. Haemost. 6:1655-1662(2008) · Mapped (7) |
| Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. King C.R., Porche-Sorbet R.M., Gage B.F., Ridker P.M., Renaud Y., Phillips M.S., Eby C. Am. J. Clin. Pathol. 129:876-883(2008) · Mapped (9) |
| CYP4F2 genetic variant alters required warfarin dose. Caldwell M.D., Awad T., Johnson J.A., Gage B.F., Falkowski M., Gardina P., Hubbard J., Turpaz Y., Langaee T.Y., Eby C. et al. Blood 111:4106-4112(2008) · Mapped (4) |
| Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., Brown R. J. Clin. Oncol. 25:4528-4535(2007) · Mapped (86) |
| Identification of NR1I2 genetic variation using resequencing. King C.R., Xiao M., Yu J., Minton M.R., Addleman N.J., Van Booven D.J., Kwok P.Y., McLeod H.L., Marsh S. Eur. J. Clin. Pharmacol. 63:547-554(2007) · Mapped (8) |
| Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Lemiale F., Haddada H., Nabel G.J., Brough D.E., King C.R., Gall J.G. Vaccine 25:2074-2084(2007) · UniProtKB (32) |
| Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Marsh S., Somlo G., Li X., Frankel P., King C.R., Shannon W.D., McLeod H.L., Synold T.W. Pharmacogenomics J. 7:362-365(2007) · Mapped (18) |
| Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Zamboni W.C., Ramanathan R.K., McLeod H.L., Mani S., Potter D.M., Strychor S., Maruca L.J., King C.R., Jung L.L., Parise R.A. et al. Invest New Drugs 24:393-401(2006) · Mapped (16) |
| Population variation in VKORC1 haplotype structure. Marsh S., King C.R., Porche-Sorbet R.M., Scott-Horton T.J., Eby C.S. J. Thromb. Haemost. 4:473-474(2006) · Mapped (2) |
| Interethnic variability of ERCC2 polymorphisms. King C.R., Yu J., Freimuth R.R., McLeod H.L., Marsh S. Pharmacogenomics J. 5:54-59(2005) · Mapped (4) |
| Distribution of ITPA P32T alleles in multiple world populations. Marsh S., King C.R., Ahluwalia R., McLeod H.L. J. Hum. Genet. 49:579-581(2004) · Mapped (3) |
| Human APC2 localization and allelic imbalance. Jarrett C.R., Blancato J., Cao T., Bressette D.S., Cepeda M., Young P.E., King C.R., Byers S.W. Cancer Res. 61:7978-7984(2001) · UniProtKB (2) |
| High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. Henry J.L., Coggin D.L., King C.R. Cancer Res. 53:1403-1408(1993) · UniProtKB (1) |
| Alpha A-crystallin messenger RNA of the mouse lens: more noncoding than coding sequences. King C.R., Shinohara T., Piatigorsky J. Science 215:985-987(1982) · UniProtKB (1) |
| Alternative RNA splicing of the murine alpha A-crystallin gene: protein-coding information within an intron. King C.R., Piatigorsky J. |
| Selective loss of a family of gene transcripts in a hereditary murine cataract. Garber A.T., Winkler C., Shinohara T., King C.R., Inana G., Piatigorsky J., Gold R.J. Science 227:74-77(1985) · Mapped (2) |
| Lens-specific expression of the chloramphenicol acetyltransferase gene promoted by 5' flanking sequences of the murine alpha A-crystallin gene in explanted chicken lens epithelia. Chepelinsky A.B., King C.R., Zelenka P.S., Piatigorsky J. Proc. Natl. Acad. Sci. U.S.A. 82:2334-2338(1985) · Mapped (3) |
| A novel human gene closely related to the abl proto-oncogene. Kruh G.D., King C.R., Kraus M.H., Popescu N.C., Amsbaugh S.C., McBride W.O., Aaronson S.A. |
| Human HER2 (neu) promoter: evidence for multiple mechanisms for transcriptional initiation. Tal M., King C.R., Kraus M.H., Ullrich A., Schlessinger J., Givol D. Mol. Cell. Biol. 7:2597-2601(1987) · UniProtKB (1) |
| Amplification of a novel v-erbB-related gene in a human mammary carcinoma. King C.R., Kraus M.H., Aaronson S.A. Science 229:974-976(1985) · UniProtKB (1) |
| Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Rosengard A.M., Krutzsch H.C., Shearn A., Biggs J.R., Barker E., Margulies I.M.K., King C.R., Liotta L.A., Steeg P.S. |